Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  CORONARY STENTS
A Global Strategic Business Report

This report analyzes the worldwide markets for Coronary Stents in Millions of US$ and Thousand Units. The major product segments analyzed are Bare Metal Stents, and Drug Eluting Stents. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2015. The report profiles 53 companies including many key and niche players worldwide such as Angiotech Pharmaceuticals, Boston Scientific Corp., Cordis Corporation (JNJ), Cook Group, Inc., Medtronic, Inc., Medtronic Vascular, Inc., MIVI Technologies Inc., OrbusNeich, Sorin Biomedica Cardio, and Sun Biomedical Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1148  PAGES:    257
PRICE:    $3950  DATE:       October 2008
COMPANIES:  53  MARKET DATA TABLES:   114
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  CORONARY STENTS (Complete Report) Pages : 257   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Market Definitions and Scope of Study.....I-3
Bare Metal Stents.....I-3
Drug Eluting Stents.....I-3
  
II. EXECUTIVE SUMMARY75$2250
  1. Global Market Overview.....II-13 $300  
   Drug Eluting Stents Steal the Show .....II-1
Cypher and Taxus Dominate Global DES Market .....II-1
1$100
   A 10-Year Outlook for the Coronary Stents Industry.....II-21$100
   Current and Future Analysis.....II-3
1$100
  2. Market Trends and Issues.....II-44 $400  
   Drug Eluting Stent System – Safety Concerns.....II-4
Drug Eluting Stent Market to Bounce Back.....II-4
Coronary Stents Market Challenged by Drug Therapy.....II-4
Restenosis - the Real Growth Driver.....II-4
1$100
   Table 1: Growth in Angioplasty Procedures Vs Stent Penetration Worldwide: (1997-2006) (includes corresponding Graph/Chart).....II-5
Small Vessels – A Major Cause of Restenosis .....II-5
Aging Population Propels Coronary Stent Market .....II-5
Cell Transplantation – A Major Threat to Coronary Stents.....II-5
1$300
   Next Generation Stents – A Boon for Treating Coronary Diseases .....II-6
Direct Stenting Systems Spur Growth.....II-6
Drug Choice Impacts Market Entry .....II-6
1$100
   Price and Quality Concerns Dog Supplies and Demand for DES .....II-7
DES’ Introduction Skyrockets Coronary Stent Prices .....II-7
Legal Challenges Right Behind .....II-7
New Competition Puts Tabs on Coronary Stenting .....II-7
1$100
  3. Competitive Analysis.....II-84 $600  
   Coronary Stents – Leading Players.....II-8
Table 2: Leading Players in the Global Coronary Stents Market (2006-2008) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, Medtronic, and Others (includes corresponding Graph/Chart).....II-8
Bare Metal Stents – Leading Players.....II-8
1$300
   Table 3: Leading Players in the Global Bare Metal Stents Market (2006-2008) – Percentage Breakdown by Revenues for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart).....II-9
Drug-Eluting Stents – Leading Players.....II-9
Table 4: Leading Players in the Global Drug-Eluting Stent Market (2006-2008) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, and Medtronic (includes corresponding Graph/Chart).....II-9
1$300
   The Big Fight Heats Up in the Coronary Stent Market – A Recent Past (2005) Anecdote
  .....II-10
2$200
  4. Product Overview.....II-1214 $900  
   Coronary Disease - A Perspective.....II-12
Factors Responsible for Coronary Diseases.....II-12
Controllable Risk Factors.....II-12
High Blood Cholesterol.....II-12
Sedentary Life Style and Habits.....II-12
Smoking Habits.....II-12
1$100
   High Blood Pressure.....II-13
Uncontrollable Risk Factors.....II-13
Age.....II-13
Heredity.....II-13
Gender.....II-13
Causative Risk Factors.....II-13
Stress and Anger.....II-13
1$100
   Obesity.....II-14
Symptoms of Coronary Artery Disease.....II-14
Diagnosis.....II-14
Treatment.....II-14
Drug Supported Treatments.....II-14
1$100
   Invasive Treatments.....II-15
Bypass Surgery.....II-15
Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty).....II-15
Natural Therapy.....II-15
1$100
   Advancements in Coronary Disease Treatment Modalities .....II-16
University of Virginia’s Microbe Solution for Post Surgical Complications.....II-16
Radiation for Re-clogged Arteries Show Promise .....II-16
Radioactive Coronary Stents Promise Bright Future .....II-16
Coronary Stents.....II-16
Introduction.....II-16
1$100
   Evolution of Coronary Stents.....II-17
Applications of Coronary Stents.....II-17
1$100
   Stent Deployment.....II-18
Key Stent Delivery Platforms by Select Company.....II-18
1$100
   Coronary Stent Designs.....II-19
Key Factors Determining Coronary Stent Performance.....II-19
Delivery Convenience.....II-19
Efficient Scaffolding.....II-19
Radiopacity (Visibility).....II-19
Optimum Flexibility.....II-19
Shape Conformability.....II-19
1$100
   Material for Coronary Stent.....II-20
Risk Associated with Stenting.....II-20
Improper Stent Implantation Likely Cause for In-Stent Restenosis.....II-20
1$100
   Precautions.....II-21
What’s New in Coronary Stent Market?.....II-21
1$100
   Direct Coronary Stenting – Creating an Enliven ......II-22
Limitations.....II-22
1$100
   Regulatory Approvals Wooing Stent Market .....II-23
A Peek into Regulatory Agency Approvals for Coronary Stents.....II-23
3$300
  5. Product Segments.....II-265 $500  
   Bare Metal Stents.....II-26
Major Bare Metal Stents by Company.....II-26
Drug-Eluting Stents.....II-26
1$100
   DE Stents Overshadow Intravascular Brachytherapy Interventions .....II-27
Major Drug-Eluting Stents by Company.....II-27
Drugs for Coating DESs.....II-27
1$100
   Cytotoxic or Cytostatic Drug – the Debate Continues .....II-28
Dosing and Deliverability Crucial for DES.....II-28
Polymer Coatings for Effective Dosing and Deliverability .....II-28
Drugs Used for DES by Major Competitors in the Stent Market.....II-28
1$100
   Leading Coronary Stent Brands.....II-29
Cypher.....II-29
Structure and Delivery Mechanism.....II-29
Taxus .....II-29
1$100
   Structure and Delivery Mechanism.....II-30
Multi-Link Vision.....II-30
BiodivYsio Added Support.....II-30
Eptifibatide ESPRIT.....II-30
1$100
  6. Research and Development.....II-312 $200  
   Extensive R&D Underway in Global Drug-Eluting Stents Market.....II-31
At the Labs .....II-31
Other Products Under Trials – A Recent Past Perspective.....II-31
OMT Developing R-stent .....II-31
Reva Developing Stainless Steel Bare-Metal Stent .....II-31
D & P Corp Developing Bovine Pericardium - Covered Stent .....II-31
1$100
   Advanced Bio Synthesizing Porous Drug - Eluting Stents .....II-32
Lombard Medical Developing PEP Coatings .....II-32
Shiga Develops Biodegradable Drug-Eluting Stent .....II-32
1$100
  7. Product Introductions.....II-333 $300  
   InspireMD - MGuard™ Coronary Stent Launched in Italy.....II-33
CeloNova BioSciences Launches CATANIA™ Coronary Stent with NanoThin
  Polyzene®-F.....II-33
Angiotech Launches Cook Medical’s Drug Eluting Zilver® PTX™ Stent in New
  Zealand.....II-33
1$100
   Boston Scientific Launches Its Own Version of XIENCE™V Drug-Eluting Coronary Stent in
  Europe.....II-34
Guidant’s New Coronary Stent System Enters Japanese Realm .....II-34
Boston’s Gears Up for Market Expansion of TAXUS Liberte .....II-34
1$100
   Trimax – A New Coronary Stent From Abbott .....II-35
JNJ Ramps Up Production of Cypher .....II-35
Occam Eyeing the International Markets .....II-35
Devax Offers Axxess Stent .....II-35
MIV Therapeutics Develops Metal Stent Coating Process .....II-35
1$100
  8. Product Launches in the Recent Past.....II-362 $200  
   Cordis Spearheads DES Revolution with the Rollout of Cypher .....II-36
New Duraflex Coronary Stent System From Avantec .....II-36
Abbott Launches Dexamet Drug-Eluting Stents in Europe .....II-36
Boston Scientific Introduces Drug-Eluting Stent in Europe .....II-36
Cordis Rolls Out Heparin Coated Coronary Stent .....II-36
Guidant Debuts Multi-Link Plus Intracoronary Stent in Japan .....II-36
1$100
   Abbott Launches BiodivYsio Coronary Stent .....II-37
Guidant Rolls Out Tiny Artery Opening Stent Systems .....II-37
SMC Develops Plastic Stents for Coronary Artery .....II-37
JNJ Develops Drug Coated Coronary Stent .....II-37
Coronary Stent Introductions: A Historical Perspective.....II-37
1$100
  9. Recent Industry Activity.....II-3810 $700  
   Medtronic Receives the US FDA Approval to Use Endeavor® Stent.....II-38
Medtronic Inc. Receives Approval for its Drug-Eluting Stent, “Endeavor” In
  Canada.....II-38
Boston Scientific to Market TAXUS® Liberte® Stent System in Canada.....II-38
Abbott Applies for Approval of XIENCE™ V in Japan.....II-38
1$100
   Medinol Achieves CE Mark Approval for Presillion™ Cobalt Chromium Coronary Stent
  System.....II-39
Iberhospitex Receives Spanish Approval to Sell Palau Pharma’s “Active” Coronary
  Stent.....II-39
Clearstream’s Intrepide Drug Eluting Stent of Clearstream Receives CE mark
  approval.....II-39
Terumo Introduces Its Drug-Eluting Stent in Germany and Marks Its European
  Entry.....II-39
Tryton Medical’s Side-Branch Stent Achieves CE Mark Approval.....II-39
1$100
   CV Therapeutics Offers its Stent Coating Technology to Medlogics Device
  Corporation.....II-40
Abbott’s 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE Mark of
  Approval.....II-40
Biosensors Receives CE Mark Approval for BioMatrix® Stent System.....II-40
Nfocus Neuromedical’s CardioVasc™ Stent-Graft and Delivery System Receives CE Mark
  Approval.....II-40
1$100
   Cook Medical’s Zilver Stent Receives Approval for Vascular Use In Canada.....II-41
Boston Scientific to Market TAXUS® EXPRESS2 Stent System in Japan.....II-41
CE Mark Granted for the Use of Drug-eluting Stent, TAXUS® Liberte™ in Diabetic
  Patients.....II-41
Boston Scientific’s TAXUS® Liberte™ Long Stent Receives CE Mark Approval.....II-41
Boston Joins Forces with Guidant .....II-41
1$100
   Avantec Licenses Blue Membranes’ Technology for DES .....II-42
FDA Nods for Usage of CYPHER® in Overlapping Stenting .....II-42
Guidant’s XIENCE™ V Gets CE Marked .....II-42
EuroCor Receives Definitive CE Mark Approval for Taxcor .....II-42
BIOTRONIK Ties Up with Novartis .....II-42
1$100
   BIOTRONIK Collaborates with Micrus .....II-43
CYPHER Select™ PLUS Gets CE Nod .....II-43
Medtronic’s Micro-Driver Bags FDA Approval .....II-43
Conor Wins CE Mark Approval for CoStar™ .....II-43
Relisys Collaborates with Blue Membranes .....II-43
1$100
   OCIL Steps Into the German Sphere by Acquiring EuroCor .....II-44
Boston Purchases Advanced Stent Technologies........II-44
Neich Medical Acquires Orbus Medical .....II-44
MIV Therapeutics To Purchase Assets of Sahajanand .....II-44
Conor’s Unistar Becomes CE Approved .....II-44
CE Clears DISA’s Small-Vessel Heart Stent .....II-44
Boston’s TAXUS Express2 for Larger Vessels Gets Lucrative Approvals .....II-44
1$100
   Boston Inaugurates R&D Center .....II-45
Endovasc Forms Joint Venture with Tissuegen .....II-45
Avantec Vascular Signs Licensing Pact With Novartis .....II-45
Boston Acquires Rights from Angiotech .....II-45
Xtent and Occam International Enter Into Licensing Deal .....II-45
1$100
   Angiotech and Cook Reorganize License Agreement .....II-46
CardioTech and Implant Sciences Join Forces .....II-46
Guidant and Cordis Sign Marketing Agreement .....II-46
CONOR and BIOTRONIK Ink Distribution Pact .....II-46
Boston Scientific Obtains FDA Approval for Taxus Stents .....II-46
1$100
   ev3 Receives CE Mark Approval for Protege Stent .....II-47
DISA Gains CE Mark Approval .....II-47
1$100
  10. Strategic Corporate Developments in the Past.....II-485 $500  
   Guidant Acquires Biosensors’ Everolimus DES Assets .....II-48
Sun Biomedical Signs Sales and Licensing Agreement with Guidant .....II-48
Debiotech Receives License for DES Technology .....II-48
JNJ Wins FDA Approval for Cypher Stent .....II-48
Medtronic Obtains FDA Approval for Driver Coronary Stent .....II-48
1$100
   Boston Receives CE Mark Approval .....II-49
Goodman Acquires Avantec .....II-49
Abbott Acquires Coronary Stent Business of Biocompatibles .....II-49
Guidant Expands Licensing Agreement with Novartis Pharma .....II-49
Abbott Signs Marketing Agreement with Medtronic .....II-49
Medtronic Sublicenses DES Coating Technology from Abbott .....II-49
Gore and Medinol Sign Collaborative Agreement .....II-49
1$100
   Guidant Obtains CE Mark Approval .....II-50
Boston Scientific Receives Marketing Approval for Coronary Stent System .....II-50
Cook Obtains CE Approval for ACHIEVE™ Coronary Stent .....II-50
Snia Receives Clearance from TGA to Market Stents and Catheters .....II-50
OCIL Acquires Key Assets of AMDL .....II-50
1$100
   Fujisawa and JOMED Join Forces .....II-51
British Biotech Enters into Collaboration with Biocompatibles .....II-51
AVI BioPharma and Medtronic Enter into Agreement .....II-51
Guidant Inks Distribution Agreement with Cook .....II-51
JNJ Wins FDA Approval for Bx Velocity Coronary Stent .....II-51
Cook Obtains Approval for Drug Coated Coronary Stent .....II-51
Medtronic Obtains FDA Approval for S660 Coronary Stent .....II-51
2$200
  11. Clinical Trials and Key Studies.....II-532 $200  
   Canadian Study Indicates Superior Clinical Benefits of Drug-Coated Stent.....II-53
SPIRIT III Trial Confirms Superiority of Everolimus Eluting Coronary Stent, XIENCE™ V
  Over TAXUS® Stent.....II-53
Network Meta-Analysis Demonstrates Low Mortality Rates for Both Drug-Eluting And
  Bare-Metal Stents.....II-53
1$100
   Study Proves Superiority of Cypher® Sirolimus-Eluting Coronary Stent in Reduction of
  Blood Clot Risks and Reintervention Compared to Taxus Stent.....II-54
1$100
  12. Focus on Select Players.....II-553 $300  
   Angiotech Pharmaceuticals (Canada).....II-55
Boston Scientific Corp. (USA).....II-55
1$100
   Cordis Corporation (JNJ) - (USA).....II-56
Cook Group, Inc. (USA).....II-56
Medtronic, Inc. (USA).....II-56
Medtronic Cardiovascular, Inc. (USA).....II-56
1$100
   MIVI Technologies Inc. (Canada).....II-57
OrbusNeich (USA).....II-57
Sorin Biomedica Cardio (Italy).....II-57
Sun Biomedical Ltd. (USA).....II-57
1$100
  13. Global Market Perspective.....II-58   
   Table 5: World Recent Past, Current & Future Analysis for Coronary Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....II-581$300
   Table 6: World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2011 (includes corresponding Graph/Chart).....II-591$300
   Table 7: World Long-Term Projections for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-601$300
   Table 8: World Long-Term Projections for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2011 through 2016 (includes corresponding Graph/Chart).....II-611$300
   Table 9: World 10-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart).....II-621$300
   Table 10: World 10-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2013 (includes corresponding Graph/Chart).....II-631$300
   Table 11: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....II-641$300
   Table 12: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2011 (includes corresponding Graph/Chart).....II-651$300
   Table 13: World Long-Term Projections for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-661$300
   Table 14: World Long-Term Projections for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2011 through 2016 (includes corresponding Graph/Chart).....II-671$300
   Table 15: World 10-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart).....II-681$300
   Table 16: World 10-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2013 (includes corresponding Graph/Chart).....II-691$300
   Table 17: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-701$300
   Table 18: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2001 through 2011 (includes corresponding Graph/Chart).....II-711$300
   Table 19: World Long-Term Projections for Drug Eluting Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-721$300
   Table 20: World Long-Term Projections for Drug Eluting Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2011 through 2016 (includes corresponding Graph/Chart).....II-731$300
   Table 21: World 10-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart).....II-741$300
   Table 22: World 10-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2013 (includes corresponding Graph/Chart).....II-751$300
III. MARKET77$1950
  1. United States.....III-118 $1275  
   A. Market Analysis.....III-1
Largest Market Worldwide .....III-1
Coronary Artery Disease - A US Perspective.....III-1
Rapid Adoption of DES Technology in the US Market.....III-1
Baby Boomers Boost Coronary Stent Market .....III-1
1$75
   Key Drivers of the US DES Market.....III-2
Improved Treatment and Diagnosis.....III-2
Long-Term Cost Reduction.....III-2
Well-Organized Reimbursement System.....III-2
Growing Patient Awareness.....III-2
DES Technology – Economic Implications on the US Health Care System .....III-2
1$75
   Soaring Costs of Multivessel Treatment – Still a Major Problem .....III-3
Competitive Scenario.....III-3
Leading Players.....III-3
Coronary Stents – Boston Scientific and JNJ Battle for Dominance.....III-3
Table 23: Leading Players in the US Coronary Stents Market (2006) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson and Others (includes corresponding Graph/Chart).....III-3
1$150
   Bare Metal Stents – Guidant Led all the Way.....III-4
Table 24: Leading Players in the US Bare Metal Stents Market (2006) – Percentage Breakdown by Revenues for Guidant (Abbott), Boston Scientific, Medtronic, Johnson & Johnson, Abbott Laboratories and Others (includes corresponding Graph/Chart).....III-4
Drug Eluting Stents – Competition in the Brewing.....III-4
Table 25: Leading Players in the US Drug-Eluting Stents Market (2006, 2007 & 2008) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Medtronic and Abbott (includes corresponding Graph/Chart).....III-4
1$150
   Regulatory Environment.....III-5
Product Introductions.....III-5
2$150
   Recent industry activity.....III-77$525
   Review of Select Players.....III-14
Boston Scientific Corp......III-14
1$75
   Cordis/JNJ.....III-15
Cook Group, Inc......III-15
Medtronic, Inc......III-15
1$75
   Sun Biomedical Ltd.....III-16
B. Market Analytics.....III-16
Table 26: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-16
1$150
   Table 27: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-17

Table 28: US Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-17
1$150
   Table 29: US Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-18

Table 30: US 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-18

Table 31: US 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-18
1$150
  2. Japan.....III-197 $725  
   A. Market Analysis.....III-19
Prospects Weighed down by Regulatory Entanglements.....III-19
Japanese Government Steps in to Alleviate Pricing.....III-19
Japanese Coronary Stents Command Higher Prices .....III-19
Table 32: Coronary Stent Pricing (2005): Comparative Analysis of Prices in Japan, US, Europe and Global Average (includes corresponding Graph/Chart).....III-19
1$150
   Competitive Landscape.....III-20
Table 33: Leading Players in the Japanese Coronary Stent Market (2004, 2005 & 2006) – Percentage Breakdown by Value Sales for Johnson & Johnson, Medtronic, Guidant, Boston Scientific, and Others (includes corresponding Graph/Chart).....III-20
1$150
   Table 34: Leading Players in the Japanese Bare Metal Stent Market (2004, 2005 & 2006) – Percentage Breakdown by Value Sales for Guidant, Medtronic, Boston Scientific, JNJ and Others (includes corresponding Graph/Chart).....III-21

Table 35: Leading Players in Japanese Drug-Eluting Stent Market (2006, 2007 & 2008) – Percentage Breakdown by Revenues for Johnson & Johnson and Boston Scientific.....III-21
1$150
   Product Introductions in the Recent Past.....III-22
Strategic Development.....III-22
1$75
   Strategic Corporate Activity in the Recent Past.....III-23
B. Market Analytics.....III-23
Table 36: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-23
1$150
   Table 37: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-24

Table 38: Japanese Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-24
1$150
   Table 39: Japanese Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-25

Table 40: Japanese 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-25

Table 41: Japanese 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-25
1$150
  3. Europe.....III-2620 $1475  
   A. Market Analysis.....III-26
Cardiovascular Disease in Europe – A Perspective.....III-26
Table 42: European Cardiovascular Disease Treatment Procedures – A Historic View.....III-26
1$150
   Growth Bar Too Low .....III-27
Table 43: Price of Stents in Europe & the United States for Years 2003-2006: A Comparison (includes corresponding Graph/Chart) .....III-27

Table 44: Average Annual Volume Growth of Coronary Stents in Europe Vs Global Average (2003-2008).....III-27
Two-Speed Europe.....III-27
1$150
   Dampeners to Rapid Adoption of DES in Europe.....III-28
Reimbursement Issues.....III-28
High Penetration Rates of Bare Metal Stents.....III-28
Skyrocketing Prices.....III-28
The Scenario Changes.....III-28
Stent Market’s Merger Mania .....III-28
Competitive Scenario.....III-28
1$75
   Table 45: Leading Players in the European Bare Metal Stent Market (2004, 2005 & 2006) – Percentage Breakdown by Value Sales for Guidant, Medtronic, Boston Scientific, Johnson & Johnson, and Others (includes corresponding Graph/Chart).....III-291$150
   Table 46: Leading Players in the European Drug- Eluting Stent Market (2004, 2005 & 2006) – Percentage Breakdown by Value Sales for Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart).....III-30
Product Introductions.....III-30
2$300
   Recent Industry Activity.....III-325$375
   B. Market Analytics.....III-37
Table 47: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-37
1$150
   Table 48: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-381$150
   Table 49: European Long-Term Projections for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-391$150
   Table 50: European Long-Term Projections for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-401$150
   Table 51: European 10-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart).....III-411$150
   Table 52: European 10-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart).....III-421$150
   Table 53: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in US$ Million for years 2001 –2010 (includes corresponding Graph/Chart).....III-43

Table 54: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in Thousand Units for years 2001 –2010 (includes corresponding Graph/Chart).....III-43
1$150
   Table 55: European Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-44

Table 56: European Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-44
1$150
   Table 57: European 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-45

Table 58: European 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-45
1$150
  3a. France.....III-463 $375  
   Market Analysis.....III-46
Table 59: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-46
1$150
   Table 60: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-47

Table 61: French Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-47
1$150
   Table 62: French Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-48

Table 63: French 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-48

Table 64: French 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-48
1$150
  3b. Germany.....III-493 $375  
   Market Analysis.....III-49
Table 65: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-49
1$150
   Table 66: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-50

Table 67: German Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-50
1$150
   Table 68: German Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-51

Table 69: German 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-51

Table 70: German 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-51
1$150
  3c. Italy.....III-523 $375  
   A. Market Analysis.....III-52
Sorin Biomedica Cardio - A Key Player.....III-52
B. Market Analytics.....III-52
Table 71: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-52
1$150
   Table 72: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-53

Table 73: Italian Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-53
1$150
   Table 74: Italian Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-54

Table 75: Italian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-54

Table 76: Italian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-54
1$150
  3d. United Kingdom.....III-553 $375  
   Market Analysis.....III-55
Table 77: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-55
1$150
   Table 78: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-56

Table 79: UK Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-56
1$150
   Table 80: UK Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-57

Table 81: UK 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-57

Table 82: UK 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-57
1$150
  3e. Spain.....III-583 $375  
   Market Analysis.....III-58
Table 83: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-58
1$150
   Table 84: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-59

Table 85: Spanish Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-59
1$150
   Table 86: Spanish Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-60

Table 87: Spanish 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-60

Table 88: Spanish 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-60
1$150
  3f. Russia.....III-613 $375  
   Market Analysis.....III-61
Table 89: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-61
1$150
   Table 90: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-62

Table 91: Russian Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-62
1$150
   Table 92: Russian Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-63

Table 93: Russian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-63

Table 94: Russian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-63
1$150
  3g. Rest of Europe.....III-643 $375  
   Market Analysis.....III-64
Table 95: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-64
1$150
   Table 96: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-65

Table 97: Rest of Europe Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-65
1$150
   Table 98: Rest of Europe Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-66

Table 99: Rest of Europe 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-66

Table 100: Rest of Europe 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-66
1$150
  4. Asia-Pacific.....III-675 $475  
   A. Market Analysis.....III-67
Coronary Stent Market in a Bubble Zone Now .....III-67
Regional Players and their DES Development Efforts.....III-67
Cost Focus Helps Stent Makers Win the Market Stunt.....III-67
1$75
   Product Launch.....III-68
Recent Industry Activity.....III-68
1$75
   B. Market Analytics.....III-69
Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-69

Table 102: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-69
1$150
   Table 103: Asia-Pacific Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-70

Table 104: Asia-Pacific Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-70
1$150
   Table 105: Asia-Pacific 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-71

Table 106: Asia-Pacific 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-71
1$150
  5. Rest of World.....III-726 $725  
   A. Market Analysis.....III-72
Market Leaders.....III-72
Table 107: Leading Players in the Rest of World Coronary Stent Market (2004, 2005 and 2006) – Percentage Breakdown by Value Sales for Johnson & Johnson, Guidant, Boston Scientific, Medtronic and Others (includes corresponding Graph/Chart).....III-72
1$150
   South Africa – Leading Players.....III-73
Table 108: Leading Players in South African Coronary Stent Market (2006) – Percentage Breakdown by Unit Sales for Johnson & Johnson, Boston Scientific, Guidant, Abbott, Sorin, and Others (includes corresponding Graph/Chart).....III-73
Recent Industry Activity.....III-73
Key Players.....III-73
2$300
   B. Market Analytics.....III-75
Table 109: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart).....III-75

Table 110: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart).....III-75
1$150
   Table 111: Rest of World Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart).....III-76

Table 112: Rest of World Long-Term Projections for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart).....III-76
1$150
   Table 113: Rest of World 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-77

Table 114: Rest of World 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012.....III-77
1$150
IV. COMPETITIVE LANDSCAPE 91$995
  
Total Companies Profiled: 53 (including Divisions/Subsidiaries - 59)

Region/Country                 Players


The United States                 33
Canada                             1
Japan                              3
Europe                            14
     France                        1
     Germany                       5
     The United Kingdom            1
     Italy                         1
     Spain                         1
     Rest of Europe                5
Asia-Pacific (Excluding Japan)     4	
Middle East                        2
Africa                             2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.